Compass Ion Advisors LLC Buys 101 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Compass Ion Advisors LLC grew its position in United Therapeutics Co. (NASDAQ:UTHR) by 3.6% in the first quarter, according to its most recent filing with the SEC. The fund owned 2,892 shares of the biotechnology company’s stock after acquiring an additional 101 shares during the period. Compass Ion Advisors LLC’s holdings in United Therapeutics were worth $664,000 as of its most recent filing with the SEC.

Several other hedge funds also recently modified their holdings of UTHR. Rise Advisors LLC bought a new position in United Therapeutics in the first quarter valued at about $32,000. GAMMA Investing LLC acquired a new position in shares of United Therapeutics in the fourth quarter valued at approximately $43,000. Janiczek Wealth Management LLC raised its holdings in United Therapeutics by 21.1% in the 1st quarter. Janiczek Wealth Management LLC now owns 482 shares of the biotechnology company’s stock valued at $111,000 after buying an additional 84 shares during the last quarter. Blue Trust Inc. boosted its position in United Therapeutics by 10.0% during the 4th quarter. Blue Trust Inc. now owns 504 shares of the biotechnology company’s stock worth $114,000 after buying an additional 46 shares during the period. Finally, Quadrant Capital Group LLC grew its holdings in United Therapeutics by 31.2% during the 4th quarter. Quadrant Capital Group LLC now owns 581 shares of the biotechnology company’s stock worth $128,000 after acquiring an additional 138 shares during the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

Wall Street Analyst Weigh In

UTHR has been the topic of a number of recent research reports. JPMorgan Chase & Co. lifted their price target on shares of United Therapeutics from $280.00 to $300.00 and gave the stock an “overweight” rating in a report on Tuesday, May 21st. The Goldman Sachs Group upped their price target on United Therapeutics from $218.00 to $240.00 and gave the company a “neutral” rating in a research report on Friday, May 3rd. HC Wainwright restated a “buy” rating and set a $300.00 price objective on shares of United Therapeutics in a research report on Thursday, May 2nd. Wells Fargo & Company upped their target price on United Therapeutics from $325.00 to $350.00 and gave the company an “overweight” rating in a report on Wednesday, June 12th. Finally, Oppenheimer raised their price target on shares of United Therapeutics from $375.00 to $400.00 and gave the stock an “outperform” rating in a report on Thursday, May 2nd. One investment analyst has rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $312.22.

United Therapeutics Price Performance

Shares of UTHR opened at $318.55 on Monday. The firm has a market cap of $14.13 billion, a PE ratio of 15.06, a price-to-earnings-growth ratio of 1.40 and a beta of 0.55. United Therapeutics Co. has a 52-week low of $208.62 and a 52-week high of $321.80. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.64 and a current ratio of 3.77. The business’s 50 day moving average price is $274.77 and its two-hundred day moving average price is $243.95.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, May 1st. The biotechnology company reported $6.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.63 by $0.54. United Therapeutics had a net margin of 42.05% and a return on equity of 18.72%. The business had revenue of $677.70 million for the quarter, compared to analyst estimates of $620.31 million. During the same period in the prior year, the firm earned $4.86 earnings per share. United Therapeutics’s revenue was up 33.7% on a year-over-year basis. On average, equities analysts anticipate that United Therapeutics Co. will post 24.73 EPS for the current year.

Insider Activity

In related news, EVP Paul A. Mahon sold 6,000 shares of the company’s stock in a transaction that occurred on Thursday, April 4th. The stock was sold at an average price of $232.37, for a total transaction of $1,394,220.00. Following the transaction, the executive vice president now directly owns 36,710 shares of the company’s stock, valued at approximately $8,530,302.70. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In related news, CEO Martine A. Rothblatt sold 15,000 shares of the company’s stock in a transaction dated Thursday, April 4th. The shares were sold at an average price of $233.27, for a total value of $3,499,050.00. Following the sale, the chief executive officer now owns 130 shares in the company, valued at approximately $30,325.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Paul A. Mahon sold 6,000 shares of the firm’s stock in a transaction dated Thursday, April 4th. The shares were sold at an average price of $232.37, for a total transaction of $1,394,220.00. Following the completion of the transaction, the executive vice president now directly owns 36,710 shares in the company, valued at approximately $8,530,302.70. The disclosure for this sale can be found here. Insiders sold a total of 126,344 shares of company stock worth $32,426,462 in the last three months. Company insiders own 12.50% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.